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Abstract
Pallido-pyramidal syndromes combine dystonia with or without parkinsonism and spasticity as 
part of a mixed neurodegenerative disorder. Several causative genes have been shown to lead to 
pallido-pyramidal syndromes, including FBXO7, ATP13A2, PLA2G6, PRKN and SPG11. In 
particular, mutations in PLA2G6 have been identified in patients with Karak syndrome, a 
neurodegenerative disorder that features ataxia, dystonia-parkinsonism, dementia and spasticity 
with neuroradiologic evidence of cerebellar atrophy and/or brain iron deposition. Some patients 
with phenotypic Karak syndrome do not have demonstrable mutations in PLA2G6. Using 
homozygosity mapping and direct sequencing in a multiplex consanguineous Saudi Arabian 
family with Karak syndrome, we identified a homozygous p.G53R mutation in C19orf12. Our 
findings expand the phenotypic spectrum associated with C19orf12 mutations.
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In 2003, Mubaidin and colleagues reported a pallido-pyramidal syndrome that consisted of 
mixed ataxia, spasticity, and extrapyramidal features, which they designated “Karak 
syndrome” after the village the index patients hailed from1. Karak syndrome (MIM 610217) 
typically begins in school-age, and initially presents with ataxia. A mixed neurodegenerative 
course then results, with progressive dementia, dystonia and/or parkinsonism, and spasticity 
ensuing. Neuroimaging demonstrates cerebellar atrophy and hypointensity of the substantia 
nigra and globus pallidus on T2-weighted MRI sequences. The index family was ultimately 
found to harbor mutations in PLA2G62 but genetic heterogeneity has been suspected. We 
report the identification of mutations in C19orf12 in a multiplex consanguineous Saudi 
kindred clinically characterized as PLA2G6-negative Karak syndrome.
Materials & Methods
Patients
The probands derived from a multiplex consanguineous Saudi pedigree (Figure 1).
Patient 1 (VII:5)—The patient was a male born at term after an unremarkable pregnancy. 
Early milestones were attained at appropriate ages, and the patient walked at age one. At 
four years of age, the patient developed an abnormal gait. A progressive motor decline 
ensued, leaving the patient reliant on a wheelchair for locomotion at age 17. Dementia 
became evident in late adolescence, with anxiety and phobias emerging at that time. 
Examination at age 20 disclosed persistent nystagmus on lateral gaze, distal muscle wasting 
of the upper and lower limbs (Figure 1), upper limb dystonia and pyramidal tract signs of the 
upper and lower limbs, with kyphoscoliosis of the cervical and thoracic spine, and flexion 
contractures of the knee joints, and pes equinovarus foot deformities bilaterally. Evoked 
motor potentials demonstrated slowed velocity and reduced amplitude. MRI demonstrated 
bilateral T2 hypointensity of the globus pallidus and substantia nigra.
Patient 2 (VII:7)—This patient is the brother of Patient 1, was also born at term after an 
unremarkable pregnancy. He walked at one year, and developed gait impairment at age 6 
years. Gait progressively declined, and cognitive impairment was noted in adolescence. 
Examination at age 15 years revealed anxiety with self-injurious behaviors, insomnia, and 
slowed vertical saccades. Bradykinesia and pyramidal tract signs were evident, and bilateral 
equinovarus deformities were noted. Echocardiogram, lipid panel, and blood smear for 
acanthocytes were negative. Nerve conduction studies (done at the age of 15 years) showed 
normal motor conduction velocity (MCV) and distal motor latency (DML) of median, ulnar 
and tibial nerves. Compound motor action potential amplitudes (CMAPs) of median and 
ulnar nerves were normal, while that of tibial nerve was slightly reduced (2.3 mV). Sensory 
nerve action potential amplitudes (SNAPs) of median, ulnar and sural nerves were normal. 
Electromyography (EMG) revealed normal findings. Visual evoked potentials (VEP), 
electroretinography (ERG) and brain auditory evoked responses (BAER) revealed normal 
results. MRI exhibited T2 hypointensity of the globus pallidus and substantia nigra.
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Patient 3 (VII:2)—This patient was also born at term, and walked at age 15 months. At age 
9, he developed ataxia and cognitive impairment. At age 10, he developed spasticity of the 
lower limbs. At the time of most recent examination at age 16, the patient exhibited gait 
impairment, bradykinesia, and pyramidal tract signs. MRI disclosed evidence of cerebellar 
atrophy in addition to T2 hypointensity of the globus pallidus and substantia nigra (Figure 
1).
Genotyping
Genomic DNA was extracted from blood using established methods. Sanger sequencing 
excluded pathogenic variants in PANK2 and PLA2G6 prior to genotyping. Primers were 
designed to span coding exons of each gene along with 10–20 bp of adjacent intronic 
sequences (sequences available upon request). Genotyping was performed on the Axiom 
platform following the manufacturer’s instructions (Affymetrix, Santa Clara, CA). 
Homozygosity mapping was performed using autoSNPa as previously described3. While 
several runs of homozygosity were identified per patient, we focused on a large run of 
homozygosity on chromosome 19 found to be shared by the affected members of the family 
and absent in unaffected members (hg19 chr19: 28281401-39670046).
Results
Sequencing
Mutations in C19orf12 have previously been shown to lead to a phenotype similar to that 
seen with PLA2G6 mutation4. As C19orf12 fell within the identified linkage interval, Sanger 
sequencing of the C19orf12 gene was performed. This analysis identified a homozygous c.
157G>A, p.G53R (NM_001031726.2) mutation in all affected family members. The G53R 
mutation falls within the protein’s putative transmembrane region as do several other 
reported pathogenic mutations (Figure 2).
In silico analysis
Although this sequence variant is listed as rs200133991 in dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP/), the variant is predicted to be “deleterious” by SIFT 
(http://sift.jcvi.org) and “probably damaging” by PolyPhen2 (http://
genetics.bwh.harvard.edu/pph2). The 1000Genomes database (http://www.
1000genomes.org/) annotates the allele frequencies of the C (G) and T (A) nucleotides 
(YRI) as: C: 0.994, T: 0.006, indicating that this sequence variant represents a rare allele. In 
addition, c.157G>A has been previously reported as pathogenic in heterozygous form5.
Short linear protein binding motifs (SLiMs) were predicted using SLiMPred6, protein 
intrinsic disorder was predicted with IUPred7 and three class protein secondary structure 
(Helix, Strand and Coil) was predicted by Distill8. Transmembrane regions were predicted 
using published algorithms9–14. In silico mutation modeling indicated that the sequence 
change would have little effect on secondary structure or short linear protein interacting 
motifs (Figure 3) suggesting that abnormal protein-lipid interactions may account for this 
mutation’s pathogenicity, perhaps by impairing insertion within the mitochondrial 
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membrane. Consistent with such a paradigm, the G53R mutation is predicted to disrupt a 
glycine zipper motif crucial for membrane interaction (Figure 3)15.
Discussion
We thus report a homozygous p.G53R mutation in C19orf12, a newly identified cause of 
neurodegeneration with brain iron accumulation (NBIA)5 in a large multiplex Saudi family 
with pallido-pyramidal syndrome. Clinically, affected members of this family were 
considered to be affected with PLA2G6-negative Karak syndrome. A novel imaging finding 
not previously reported in C19orf12-associated NBIA seen in this family was cerebellar 
atrophy. In addition, all affected patients presented with ataxia that was later overshadowed 
by spasticity and dystonia-parkinsonism. There was no evidence of optic atrophy or 
peripheral neuropathy in the case (Patient 2) who had detailed neurophysiologic testing at 
the age of 15 years. Nevertheless, evoked motor potentials demonstrated slowed velocity 
and reduced amplitude in Patient 1 at the age of 20 years, suggesting that the distal muscle 
wasting found on examination (Figure 1) is due to a central axonopathy rather than 
peripheral nerve involvement.
Our findings indicate that mutations in C19orf12 should be considered in the differential 
diagnosis of patients presenting with pallido-pyramidal syndromes. Unlike patients with 
mutations in FBXO7, SPG11 and PRKN, who can also present with a pallido-pyramidal 
syndrome16, patients with C19orf12 mutations typically exhibit brain iron deposition in the 
globus pallidus and substantia nigra similar to many patients with PLA2G6 mutations. 
Patients with ATP13A2 typically also present with pallido-pyramidal syndrome, but only 
rarely demonstrate accumulation of brain iron17. C19orf12 can thus be considered in cases 
of PLA2G6-negative Karak syndrome. Although Karak syndrome is classified as a form of 
NBIA, it is important to recognize that many patients with mutations in PLA2G6 do not 
feature brain iron deposition, and it is not known whether iron deposition in the brain is an 
invariant feature of C19orf12-associated disease. Finally, it remains to be seen whether gene 
mutations that lead to similar clinical presentations will be found to intersect in common 
pathways at the molecular level.
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• The pallido-pyramidal syndrome is genetically heterogeneous
• We report a new family with pallido-pyramidal syndrome and mutations in 
C19orf12
• This mutation disrupts a glycine zipper motif crucial for protein-lipid interaction
• Mutations in C19orf12 lead to a mixed movement disorder phenotype
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• Although mutations in PLA2G6 have been shown to lead to Karak syndrome, an 
autosomal recessive pallido-pyramidal syndrome, the syndrome is genetically 
heterogeneous
• We report homozygosity mapping and candidate gene sequencing in a 
consanguineous family with Karak syndrome, leading to the identification of a 
homozygous p.G53R mutation in C19orf12
• This mutation is predicted to disrupt a glycine zipper motif crucial for protein-
lipid interactions important for the normal function of this transmembrane 
protein
• Mutations in C19orf12 can thus lead to a mixed movement disorder phenotype, 
combining spasticity, ataxia, dystonia, and parkinsonism with cerebellar atrophy 
on MRI
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Figure 1. Index family
(A) Family pedigree. (B) Distal wasting of the upper limbs. Atrophy of the thenar and 
hypothenar muscles. (C) MRI features of affected individuals. MRI from patient 3 
demonstrates T2 hypointensity of the globus pallidus, substantia nigra, and cerebellar 
atrophy consistent with Karak syndrome.
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Figure 2. Catalog of C19orf12 mutations
Shown are reported mutations5,18–21, including the present one based on UniProtKB 
Q9NSK7. Mutations cluster around the putative transmembrane region.
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Figure 3. In silico analysis of the effect of p.G53R on protein binding regions, secondary 
structure, intrinsic disorder and transmembrane domain prediction
There is little change in the predicted secondary structure, protein disorder or short linear 
protein-binding motifs (SLiMs). Although some algorithms predicted no or small changes in 
the putative transmembrane (TM) region [MEMSAT-SVM/MEMSAT3 (magenta), PRO 
(cyan), PRODIV (blue), PolyPhobius (yellow), PHDhtm (orange), SMART/TMHMM 
(green), UniProt (red)], C19orf12 is annotated by Pfam as a glycine zipper-containing 
OmpA-like membrane domain. Glycine-zipper motifs (typically GxxxGxxxG repeats) 
strongly drive right-handed helix packing and mutations in the motif can block channel 
formation15. The p.G53R mutation disrupts this important structural motif, possibly 
disrupting TM region architecture (as shown by changes in TM region prediction).
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